ClinicalTrials.gg

ALK-Abelló A/S clinical trials

Part of Lundbeckfond Invest A/S, which holds 40.3% of capital; 67.2% of voting rights as of 2025-12-31. Source

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 72 studies whose lead sponsor is ALK-Abelló A/S or one of 3 companies grouped under it. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 5, 2026.

Our grouping of 4 registry names, not the registry’s. See them and correct one ↓

Compare ALK-Abelló with Viatris and Inmunotek S.L. →

Pipeline: 1 program

Each counted once: 1 with a study ALK-Abelló A/S leads registered in the last two years.

  • Phase 3

The 1 phase-3 program — sign in to see them, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of ALK-Abelló A/S’ own registered studies; ALK-Abelló A/S’ own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs ALK-Abelló A/S’ studies test, most studies first; none is open now — 7 drugs with a page of their own. Each count opens the studies in search.

Studies, none open

All 72 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now23%Enrolling by invitation 1 · Recruiting 1
  • Completed6793%
  • Stopped early23%
  • Status unknown or other11%

Phase

  • Phase 339
  • Phase 224
  • Phase 46
  • Phase 16

Where

  • Germany18
  • Spain13
  • France9
  • Denmark8
  • Poland7
  • United States6

Over the years

  1. 07
  2. 08
  3. 09
  4. 10
  5. 911
  6. 12
  7. 13
  8. 14
  9. 15
  10. 16
  11. 17
  12. 18
  13. 19
  14. 20
  15. 21
  16. 22
  17. 23
  18. 24
  19. 25
  20. 026

By the year each study started; 13 started before 2007. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to ALK-Abelló A/S.

  • ALK-Abelló A/S
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    67 studies
  • Artu Biologicals
    Acquired
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    3 studies →
  • AllerQuest LLC
    Acquired — became part of ALK-Abelló A/S, 2024 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →
  • ALK Nordic A/S, Danmark Filial
    Regional office
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →

Focus areas

Conditions ALK-Abelló A/S leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 72. Browse all 72 →